The concept of “market stimulus”—the idea that free markets can play a role in widening access to new technologies—may help support the view that parents should be permitted to purchase germ-line enhancements. However, a critical examination of the topic shows that market stimulus, even if it applies to human genomic interventions, does not provide sufficient reason for deregulating germ-line enhancements because: (1) it could widen the gap between the rich and the poor; (2) even if it does not widen the gap, it might not sufficiently benefit the poor; and (3) it could have harmful effects for future generations.